Health
mRNA Vaccine for Deadly Nipah Virus Shows Strong Immune Response in Phase 1 Trial
A new mRNA vaccine targeting the Nipah virus—one of the world's most feared potential pandemic pathogens—proved safe and generated strong immune responses lasting at least one year in a phase 1 clinical trial published in Nature Medicine.
Key Takeaways
- An mRNA vaccine (mRNA-1215) for the Nipah virus was safe and generated sustained immune responses lasting at least one year in a phase 1 trial
- Nipah virus has a 40-75% case fatality rate and is on the WHO's priority pandemic preparedness list
- The mRNA platform allows rapid redesign if new Nipah variants emerge, making it a strong candidate for stockpile-based pandemic preparedness
DE
DT Editorial AI··via nature.com